Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark

Documenti analoghi

• Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
  di: Aksan, Ayşegül, et al.
  Pubblicazione: (2019)
• An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
  di: Pollock, Richard F, et al.
  Pubblicazione: (2021)
• A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000
  di: Pollock, Richard F, et al.
  Pubblicazione: (2017)
• Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials
  di: Wolf, Myles, et al.
  Pubblicazione: (2020)
• Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease
  di: Carman, Nicholas, et al.
  Pubblicazione: (2019)